ProCE Banner Activity

CME

Systemic Sclerosis Interstitial Lung Disease: Early Diagnosis and Comprehensive Management

Multimedia
Interstitial lung disease (ILD) is a frequent complication of the autoimmune disorder systemic sclerosis (SSc). SSc-ILD remains a challenging condition to identify, treat, and manage. Early identification of ILD in patients with SSc is critical so that treatment can be initiated as soon as possible. However, utilization of optimal screening and diagnosis strategies is low among healthcare providers. Treatment decisions also represent a significant clinical challenge; a lack of guidance and effective treatments results in suboptimal practice and gaps in knowledge among providers. While new agents are on the horizon, dissemination of clinical trial data and uptake of new agents may be delayed. Monitoring of SSc-ILD patients is equally difficult, and research suggests suboptimal practice related to this aspect of care. Finally, poor patient-provider communication amplifies these challenges and contributes to patient anxiety.

Physicians : maximum of 1.00 AMA PRA Category 1 {Credit}

Released: September 30, 2019

Expiration: September 30, 2020

No longer available for credit.

Share

Faculty

Flavia Castelino

Flavia Castelino, MD

Director, Scleroderma Program
Massachusetts General Hospital
Assistant Professor of Medicine
Harvard Medical School
Boston, Massachusetts

Jane E. Dematte

Jane E. Dematte, MD, MBA

Professor of Medicine
Northwestern University
Feinberg School of Medicine
Director, Interstitial Lung Disease Program
Division of Pulmonary and Critical Care Medicine
Chicago, Illinois

Provided by

Provided by Purdue University College of Pharmacy
ProCE Banner

Supporters

This activity is supported by an independent educational grant from

Boehringer Ingelheim

Target Audience

Rheumatologists, pulmonologists, dermatologists, and other healthcare professionals who may encounter and/or treat patients with SSc-ILD.

Learning Objectives

Upon completion of this activity, participants should be able to:
  • Discuss the epidemiology of ILD in patients with systemic sclerosis.
  • Describe the screening and diagnostic evaluation of patients with SSc for ILD.
  • Examine management options for ILD in patients with SSc.
  • Review how to monitor progression of ILD and treatment response in SSc-ILD.
  • Develop strategies to improve clinician communication with patients with SSc-ILD about their disease.

Program Director Disclosure

Program Director

Flavia Castelino, MD

Director, Scleroderma Program
Massachusetts General Hospital
Assistant Professor of Medicine
Harvard Medical School
Boston, Massachusetts

Dr. Castelino discloses the following: Consultant: Boehringer-Ingelheim Grants/Research Support: Scleroderma Research Foundation

Faculty Disclosure

Primary Author

Jane E. Dematte, MD, MBA

Professor of Medicine
Northwestern University
Feinberg School of Medicine
Director, Interstitial Lung Disease Program
Division of Pulmonary and Critical Care Medicine
Chicago, Illinois

Dr. Dematte discloses the following: Advisory Board Membership: Boehringer-Ingelheim Honorarium Recipient: Boehringer-Ingelheim

Instructions for Credit

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the Purdue University College of Pharmacy and MCM Education. Purdue University is accredited by the ACCME to provide continuing medical education for physicians.

Purdue University designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Additional Information

Participation in this self-study activity should be completed in approximately 1 hours. To successfully complete this activity and receive credit, participants must follow these steps during the period from September 30, 2019, through September 30, 2020:

1. Register online at http://www.clinicaloptions.com.
2. Read the target audience, learning objectives, and faculty disclosures.
3. Study the educational activity online or printed out.
4. Submit answers to the posttest questions and evaluation questions online.

You must receive a test score of at least 70% and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the posttest confirmation page. Records of all CME/CE activities completed can be found on the "CME/CE Manager" page. There are no costs/fees for this activity.

Program Medium

This program has been made available online.